Back

The effect of proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors on endothelial progenitor cells

2 September 2019 (08:48 - 09:06)
Organised by:
Congress Presentation Part of: PCSK9 inhibitors: from cells to patients Lipid-Lowering Agents ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Osnat Itzhaki Ben Zadok

Rabin Medical Centre, Petah Tikva (Israel)

4 More presentations in this session

Presentation thumbnail
State of the Art - PCSK9 in inhibitors therapy in clinical therapy
Professor S. Nicholls (Melbourne, AU)
Slides Video
Presentation thumbnail
The effect of monoclonal antibodies against PCSK9 on circulating CD34+ progenitor cells interactions with platelets in patients with familial hypercholesterolemia.
Mrs A. Tsouka (Ioannina, GR)
Abstract Slides Video
Presentation thumbnail
Treatment of Hypercholesterolaemia with PCSK9 Inhibitors in Denmark. Assessment of real-life data; Extent and Efficacy after the first years of clinical use
Doctor S. Mulverstedt (Copenhagen, DK)
Abstract
Presentation thumbnail
Positioning PCSK9 inhibitors therapy in clinical practice.
Professor K. Ray (London, GB)
Slides Video

Access the full session

Session thumbnail
PCSK9 inhibitors: from cells to patients

The Event

Event poster

ESC Congress 2019

2 September 2019 08:48 CET
You may be interested in
thumbnail
Congress Presentation
Where are we now? Decision-making in LDL-C lowering and CV risk
thumbnail
Webinar
Unmet needs in lipid management: treatment goals and how to achieve them
thumbnail
Congress Presentation
2025 Focused Update of the 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources